Krystal Biotech Stock

Krystal Biotech EBIT

The EBIT of Krystal Biotech (KRYS) as of Aug 8, 2026 is 161.30 M USD. In the previous year, EBIT was 65.70 M USD — a change of 145.52% (higher).

EBIT

161.30 MUSD

YoY

145.52%

Last updated:

In 2026, Krystal Biotech's EBIT was 161.30 M USD, a 145.52% increase from the 65.70 M USD EBIT recorded in the previous year.

The Krystal Biotech EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-109.73 base
Jan 1, 2024
65.70 base
Jan 1, 2025
161.30 base
Jan 1, 2026 (e)
189.23 base
Jan 1, 2027 (e)
240.83 base
Jan 1, 2028 (e)
312.92 base
Jan 1, 2029 (e)
495.83 base
Jan 1, 2030 (e)
647.95 base
YEAREBIT (M USD)
2030 est 647.95
2029 est 495.83
2028 est 312.92
2027 est 240.83
2026 est 189.23
2025 161.30
2024 65.70
2023 -109.73
2022 -145.20
2021 -68.28
2020 -33.00
2019 -22.08
2018 -11.92
2017 -4.77
2016 -1.14
Access this data via the Eulerpool API

Krystal Biotech Revenue

Krystal Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
50.70 M USD
-109.73 M USD
10.93 M USD
Jan 1, 2024
290.52 M USD
65.70 M USD
89.16 M USD
Jan 1, 2025
389.13 M USD
161.30 M USD
204.83 M USD
Jan 1, 2026 (e)
513.61 M USD
189.23 M USD
217.63 M USD
Jan 1, 2027 (e)
653.68 M USD
240.83 M USD
275.33 M USD
Jan 1, 2028 (e)
849.36 M USD
312.92 M USD
358.55 M USD
Jan 1, 2029 (e)
1.35 B USD
495.83 M USD
704.70 M USD
Jan 1, 2030 (e)
1.76 B USD
647.95 M USD
973.76 M USD

Krystal Biotech Margins

Krystal Biotech stock margins

The Krystal Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Krystal Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Krystal Biotech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
93.90 %
-216.43 %
21.56 %
Jan 1, 2024
93.09 %
22.61 %
30.69 %
Jan 1, 2025
92.61 %
41.45 %
52.64 %
Jan 1, 2026 (e)
92.61 %
36.84 %
42.37 %
Jan 1, 2027 (e)
92.61 %
36.84 %
42.12 %
Jan 1, 2028 (e)
92.61 %
36.84 %
42.21 %
Jan 1, 2029 (e)
92.61 %
36.84 %
52.36 %
Jan 1, 2030 (e)
92.61 %
36.84 %
55.37 %

Krystal Biotech Stock analysis

What does Krystal Biotech do? Krystal Biotech Inc was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company specializes in the development and commercialization of gene therapy products. It has several divisions, including dermatological and musculoskeletal diseases, as well as Ebenezer and X-Linked Retinoschisis. In the history of the company, there have been several milestones. In 2017, the company completed its first financing round, raising $8 million. In the same year, it became the first company to successfully treat a patient with its gene therapy for epidermolysis bullosa. This was a major breakthrough as this disease is otherwise difficult to treat. In 2018, the company went public on the Nasdaq, raising over $50 million. In 2019, Krystal Biotech began developing a gene therapy product for hereditary angioedema. The company's business model is primarily based on the discovery and development of gene therapy products targeting genetic defects. The goal is to treat diseases that are otherwise difficult or impossible to treat. Krystal Biotech emphasizes that it follows a patient-centric approach in the development of its gene therapy products. Another part of the business model is collaborating with partner companies and institutions to advance the development and commercialization of its products. Krystal Biotech Inc has several divisions. The first division focuses on dermatological diseases. Its gene therapy products are designed to treat epidermolysis bullosa and Netherton syndrome. Epidermolysis bullosa is a rare disease caused by a mutation in collagen and other proteins, leading to blistering and lesions on the skin. Netherton syndrome is a disease that can also cause skin rashes and allergic reactions. Krystal Biotech offers gene therapy products to reduce the symptoms of these diseases and improve patients' quality of life. Another division is musculoskeletal diseases. Krystal Biotech Inc has developed gene therapy products to treat patients with osteoarthritis and sickle cell anemia. Osteoarthritis is a painful condition caused by the breakdown of cartilage in the joint. The gene therapy products offered by Krystal Biotech are intended to promote the regeneration of cartilage cells and support joint preservation. Sickle cell anemia is an inherited disease that causes red blood cells to have an abnormal shape and can block blood vessels. Krystal Biotech's gene therapy products are intended to reduce the risk of painful crises caused by this condition. Another division of Krystal Biotech is Ebenezer and X-Linked Retinoschisis. This is an inherited condition that affects vision. Krystal Biotech has developed gene therapy products to treat this problem. Overall, Krystal Biotech Inc has conducted promising research projects. The company has core expertise in gene therapy and can apply its innovations to various medical fields. The gene therapy products offered by Krystal Biotech are intended to improve patients' lives and treat diseases that are otherwise difficult to cure. Krystal Biotech is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Krystal Biotech's EBIT

Krystal Biotech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Krystal Biotech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Krystal Biotech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Krystal Biotech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Krystal Biotech stock

EBIT of Krystal Biotech is 161.30 M USD in 2026.

EBIT of Krystal Biotech changed from 65.70 M USD to 161.30 M USD, representing a 145.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Krystal Biotech since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Krystal Biotech historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Krystal Biotech

All Key Metrics — Krystal Biotech